Tokyo, April 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061039) titled 'Clinical implications of the framework for early detection of atrial fibrillation and initiation of anti-coagulation therapy using the risk alert system derived from electrocardiogram analyzed with artificial intelligence (CVI ARO 19)' on April 1.
Study Type:
Observational
Primary Sponsor:
Institute - The Cardiovascular Institute
Condition:
Condition - Patients visiting a cardiovascular specialty hospital
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate the availability of real-time risk alert for atrial fibrillation using AI-enhanced ECG by comparing the rate of screening test, detection rate of atria fibrillation, rate of prescription of DOAC, and prognosis before and after implementation of the risk alert system.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - All the ambulant patients in our hospital who underwent ECG who consented to participate in the study
Key exclusion criteria - Patients who do not consent to participate in the study
Target Size - 5000
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2023 Year 01 Month 12 Day
Date of IRB - 2023 Year 03 Month 28 Day
Anticipated trial start date - 2023 Year 04 Month 01 Day
Last follow-up date - 2028 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069564
Disclaimer: Curated by HT Syndication.
